Fulcrum Therapeutics, Inc. (FULC)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Fulcrum Therapeutics, Inc. (FULC)
Company Performance

Current Price

as of Oct 16, 2024

$3.62

P/E Ratio

N/A

Market Cap

$225.89M

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerFULC
  • Price$3.62-1.09%

Trading Information

  • Market Cap$225.89M
  • Float84.51%
  • Average Daily Volume (1m)1,269,595
  • Average Daily Volume (3m)1,658,087
  • EPS-$0.33

Company

  • Revenue$81.63M
  • Rev Growth (1yr)8,990.91%
  • Net Income$55.41M
  • Gross Margin99.50%
  • EBITDA Margin66.12%
  • EBITDA$52.89M
  • EV$130.11M
  • EV/Revenue1.59
  • P/EN/A
  • P/S2.82
  • P/B0.82
Documents